Pfizer Inc PFE:NYSE (Common Stock)

LastDaily Change / % ChangeDividend YieldVolumeAvg Volume (10 day)
36.42 0.18   0.50%3.53%17,502,24514.8M
Market data is delayed by at least 15 minutes.
Summary chart showing the current equity's performance of over the past 1 days
  • Advanced Charts
  • Embed the above chart in your blog or website

    Customize, copy, and then paste the generated code into your website.

Market is closed. Chart as of 02:59 PM ET 10/20/2017 (03:59 PM 10/20/2017 Eastern Standard Time)

Latest News Headlines for Pfizer Inc

Stock Performance Review on Drug Makers Industry -- Pfizer, Sanofi, Heron Therapeutics, and Aerie Pharma

NEW YORK, October 20, 2017 /PRNewswire/ -- If you want a Stock Review on PFE, SNY, HRTX, or AERI then come over to and sign up for your free customized report. On Thursday, the NASDAQ Composite ended the day at 6,605.07, down 0.29%; the Dow Jones Industrial Average edged 0.02% higher, to finish at 23,163.04; and the S&P 500 closed at 2,562.10, marginally gaining 0.03%. US markets saw five out of nine sectors finishing the day in red, three in green, and one in neutral territory. has initiated research reports on the following Drug Manufacturers - Major stocks: Pfizer Inc. (NYSE: PFE), Sanofi (NYSE: SNY), Heron Therapeutics Inc. (NASDAQ: HRTX), and Aerie Pharmaceuticals Inc. (NASDAQ: AERI). Daily Stock Tracker published comprehensive and free research reports on these stocks today at:

Pfizer Presents Full Results from Phase 2 Study of Next-Generation Investigational ALK-Inhibitor Lorlatinib in ALK-Positive and ROS1-Positive Advanced Non-Small Cell Lung Cancer

A further description of risks and uncertainties can be found in Pfizer's Annual Report on Form 10-K for the fiscal year ended December 31, 2016 and in its subsequent reports on Form 10-Q, including in the sections thereof captioned "Risk Factors" and "Forward-Looking Information and Factors That May Affect Future Results", as well as in its subsequent reports on Form 8-K, all of which are filed with the U.S. Securities and Exchange Commission and available at and .

U.S. FDA Approves LYRICA(R) CR (pregabalin) Extended-Release Tablets CV

New formulation may offer convenience to patients NEW YORK--(BUSINESS WIRE)--October 12, 2017-- Pfizer Inc. (NYSE: PFE) announced today that the United States Food and Drug Administration (FDA) has approved LYRICA(R) CR (pregabalin) extended-release tablets CV as once-daily therapy for the management of neuropathic pain associated with diabetic peripheral neuropathy (pDPN) and the management of postherpetic neuralgia (PHN). LYRICA CR did not receive approval for the management of fibromyalgia.

View more recent headlines

Peers Information HelpPFE Pfizer Inc vs. Peers

Pfizer Inc
Roche Holding Ltd. (ADR)
Novartis AG (ADR)
Merck & Co., Inc.
Bayer AG (ADR)
Pfizer Inc
Roche Holding Ltd. (ADR)
Novartis AG (ADR)
Merck & Co., Inc.
Bayer AG (ADR)
Pfizer Inc
Roche Holding Ltd. (ADR)
Novartis AG (ADR)
Merck & Co., Inc.
Bayer AG (ADR)
Compare these stocks

Latest Annual and Quarterly SEC Filings

More Filings

This report contains detailed information about the company's business finances and management.


Quarterly reports contain financial statement, a discussion from management and a list of company events (stock splits, acquisitions, etc.)

Company Background

Pfizer Inc. (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). IH focuses on developing and commercializing medicines and vaccines, as well as products for consumer healthcare. IH therapeutic areas include internal medicine, vaccines, oncology, inflammation and immunology, rare diseases and consumer healthcare. EH includes legacy brands, branded generics, generic sterile injectable products, biosimilars and infusion systems. EH also includes a research and development (R&D) organization, as well as its contract manufacturing business. Its brands include Prevnar 13, Xeljanz, Eliquis, Lipitor, Celebrex, Pristiq and Viagra.


collapse, right-facing arrow indicating collapsed view of sectionOverview

A table providing an overview of the stock
Bid | Size-- | --
Ask | Size-- | --
Price Open36.30
Previous Close36.24
Day High36.42
Day Low36.03
52 Week High10/12/2017 | 36.60
52 Week Low11/3/2016 | 29.83
% Off 52 Week High-0.49%
% Off 52 Week Low22.09%
Beta (5 Yr)0.99
Volatility Avg10/20/2017 | 15.03
10-Day Avg. Volume14,775,322
Market data is delayed by at least 15 minutes.

collapse, right-facing arrow indicating collapsed view of sectionFundamentals

A table providing the fundamentals of the stock
EPS (TTM)7/2/2017 | 1.37
P/E Ratio7/2/2017 | 26.4
Market CapMega Cap | 216.89B
Shares Outstanding5.96B

collapse, right-facing arrow indicating collapsed view of sectionDividends

A table providing information about the dividends of the stock
Dividend Yield3.53%
Dividend Announcement9/27/2017
Date of Record11/10/2017
Payable$0.32 - QRTR
Payable Date12/1/2017

collapse, right-facing arrow indicating collapsed view of sectionShare Statistics

A table providing statistics about shares of the stock
Shares Short49.00M
Short Ratio2.8
Short % of Float0.83%
As of 9/29/2017
The performance data quoted represents past performance. Past performance does not guarantee future results. Current performance may be lower or higher than the performance quoted. Investment return and principal value of an investment will fluctuate and when redeemed, the investment may be worth more or less than their original cost.
The research, tools, and information provided will not include every security available to the public.